Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NCT04007835 · clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
120
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Guangdong Association of Clinical Trials

Collaborators